GeoVax Labs, Inc. 2026: Revenue $0 EPS ($0.97) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.GeoVax Labs reported Q2 2026 results with $0 revenue and a net loss of $4.43M, an 17.6% improvement year-over-year. The company discontinued GEO-CM04S1 to focus on lead vaccine GEO-MVA, advancing to Phase 3 per EMA advice, and Gedeptin for HNSCC. Manufacturing modernization efforts continue via a continuous avian cell line. With the prior BARDA contract terminated, GeoVax relies on equity financings and grants.
GeoVax Labs, Inc. reported results for the 2026 quarter showing no revenue and a reduced net loss versus the prior-year period as the company shifts focus to its lead vaccine and oncolytic programs.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $0 | $852.28K | (100%) |
| Net income² | ($4.43M) | ($5.37M) | 17.6% |
| Diluted EPS³ | ($0.97) | ($8.74) | 88.9% |
¹ Reported as “Revenue from government contract”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per common share”.
Business Highlights
- GEO‑MVA: Advancing to Phase 3 per EMA advice with a target start in late 2026 to address global orthopox vaccine supply.
- Portfolio reprioritization: Discontinued GEO‑CM04S1 to concentrate resources on GEO‑MVA and the oncolytic candidate Gedeptin.
- Gedeptin development: Completed Phase 1/2 in head and neck squamous cell carcinoma (HNSCC); planning a Phase 2 neoadjuvant combination study targeting 2027 initiation.
- Manufacturing modernization: Developing a continuous avian cell line for scalable cGMP MVA production to improve yield and responsiveness.
- Revenue & funding: No product sales this quarter; prior BARDA contract was terminated and the company is relying on equity financings and grants for funding.
Original SEC Filing: GeoVax Labs, Inc. [ GOVX ] - 10-Q - Jul. 27, 2026